This post was written by OneMedPlace Team
BOTHELL, WA—January 8, 2013—BioLife Solutions (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer today announced that DHI Global Medical Group has incorporated BioLife’s proprietary HypoThermosol cell/tissue storage and shipping medium to improve ex-vivo survival of hair grafts during a transplantation procedure.
Mike Rice, BioLife Solutions Chief Executive Officer, said, “We have spent the past few years building the value of HypoThermosol as an important biopreservation medium in hair restoration and we believe 2013 will be the year that this market becomes a significant revenue stream for BioLife Solutions. We are very pleased to support DHI Global in its continuous quality improvement initiative. DHI Global joins a growing number of hair restoration clinicians and professionals who understand the value and benefits of transitioning from non-optimized graft storage solutions to using HypoThermosol, which is engineered to better protect cells and tissues exposed to hypothermic biopreservation conditions.
Leading hair restoration surgeons around the world have adopted HypoThermosol after seeing improved graft survival and increased patient satisfaction.”
DHI Global has committed purchase volumes of HypoThermosol for the full year 2013 for its offices in Paris, London, and Athens, with a goal of establishing use of HypoThermosol as a standard of care through its network of more than 30 global locations.
The International Society of Hair Restoration Surgery (ISHRS) estimates that 279,381 surgical hair restoration procedures were performed worldwide in 2010.
About DHI Global Medical Group
Founded in 1970 with now over 30 worldwide affiliated locations, DHI Global Medical Group hair restoration professionals have performed over 150,000 procedures. The company was founded by Mr. K.P. Giotis in Palo Alto, California and has been dedicated solely to the research, diagnosis and treatment of hair and scalp disorders. 42 years later, the DHI technique offers hair loss sufferers across the globe a painless procedure with natural results. For more information please visit www.dhiglobal.com
About BioLife Solutions
BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues. The Company’s proprietary HypoThermosol^® and CryoStor^® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife’s products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife’s enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions’ actual results to differ materially are discussed in the Company’s recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.